Literature DB >> 14663304

Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy.

Yoav Vardizer1, Yifat Linhart, Anat Loewenstein, Hanna Garzozi, Nail Mazawi, Anat Kesler.   

Abstract

The authors describe one patient with essential thrombocytosis and one with chronic hepatitis C infection who developed bilateral simultaneous anterior ischemic optic neuropathy within 3 months of starting treatment with interferon-alpha. One patient had several typical risk factors for conventional AION; the other did not. These cases are the fourth and fifth reported examples of this phenomenon. Interferon-alpha treatment may cause or aggravate the risk of developing anterior ischemic optic neuropathy. Vulnerable patients should be advised of this potential complication, assisted in reducing risk factors, and monitored for optic nerve and retinal vascular complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663304     DOI: 10.1097/00041327-200312000-00003

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  10 in total

1.  Bilateral juxtapapillary choroidal neovascularisation associated with interferon alfa treatment of a metastatic cutaneous melanoma.

Authors:  J Garcia-Arumi; M Morral Palau; M Montolio Gil; H Blasco Garrido; L Sararols Ramsay; A Segura García
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

2.  Pegylated interferon alpha-associated optic neuropathy.

Authors:  Kathleen T Berg; Bruce Nelson; Andrew R Harrison; Linda K McLoon; Michael S Lee
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

3.  Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon.

Authors:  Michael R Narkewicz; Philip Rosenthal; Kathleen B Schwarz; Arlene Drack; Todd Margolis; Michael X Repka
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-08       Impact factor: 2.839

4.  Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy.

Authors:  N R Miller; A C Arnold
Journal:  Eye (Lond)       Date:  2014-07-04       Impact factor: 3.775

5.  Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.

Authors:  Deng-Huang Su; Ying-Chun Chang; Shu-Lang Liao; Tien-Chun Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09-28       Impact factor: 3.117

6.  Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?

Authors:  Valerie Touitou; Damien Sene; Christine Fardeau; Thi-Huong-Du Boutin; Pierre Duhaut; Jean-Charles Piette; Phuc LeHoang; Patrice Cacoub; Bahram Bodaghi
Journal:  Int Ophthalmol       Date:  2007-02-23       Impact factor: 2.029

7.  Immunoprofiling of Nonarteritic Anterior Ischemic Optic Neuropathy.

Authors:  Louise A Mesentier-Louro; Laurel Stell; Yan Yan; Artis A Montague; Vinicio de Jesus Perez; Yaping Joyce Liao
Journal:  Transl Vis Sci Technol       Date:  2021-07-01       Impact factor: 3.048

8.  Bilateral Ischemic Optic Neuropathy Developed under Interferon Therapy.

Authors:  Fatih Selcukbiricik; Deniz Tural; Tuba Elif Senel; Ahmet Sarıca; Ozlem Soyluk; Suheyla Serdengecti
Journal:  Case Rep Ophthalmol Med       Date:  2012-10-18

9.  Transient visual loss in a hepatitis C patient treated with pegylated interferon alfa-2a and ribavirin.

Authors:  Ligita Jancoriene; Dovile Norvydaite; Saulius Galgauskas; Evelina Balciunaite
Journal:  Hepat Mon       Date:  2014-02-20       Impact factor: 0.660

Review 10.  Ocular toxicity of systemic anticancer chemotherapy.

Authors:  Afekhide Ernest Omoti; Caroline Edijana Omoti
Journal:  Pharm Pract (Granada)       Date:  2006-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.